On the basis of previous studies that showed certain sigma-2 agonists to be quite effective in preclinical tumor models of pancreatic cancer [21–24], we selected five sigma-2 ligands (Fig. 1, PB28, PB183, PB221, F281 and PB282). The gene discussed is AP2S1; the disease is pancreatic neoplasm.